Targeting FLT3 kinase in acute myelogenous leukemia: Progress, perils, and prospects

被引：12

作者：

Heinrich, MC

机构：

[1] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA

[2] Portland VA Med Ctr, Portland, OR 97201 USA

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2004年 / 4卷 / 03期

关键词：

FLT3; tyrosine kinase; kinase inhibitor; AML; KIT; PDGFR;

D O I：

10.2174/1389557043487394

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

引用

收藏

页码：255 / 271

页数：17

相关论文

共 152 条

[61] Theme and variations: Juxtamembrane regulation of receptor protein kinases [J].

Hubbard, SR .

MOLECULAR CELL, 2001, 8 (03) :481-482

[62] FLT3/FLK2 LIGAND PROMOTES THE GROWTH OF MURINE STEM-CELLS AND THE EXPANSION OF COLONY-FORMING CELLS AND SPLEEN COLONY-FORMING-UNITS [J].

HUDAK, S ;

HUNTE, B ;

CULPEPPER, J ;

MENON, S ;

HANNUM, C ;

THOMPSONSNIPES, LA ;

RENNICK, D .

BLOOD, 1995, 85 (10) :2747-2755

[63] Reversibility of acute B-cell leukaemia induced by BCR-ABL1 [J].

Huettner, CS ;

Zhang, P ;

Van Etten, RA ;

Tenen, DG .

NATURE GENETICS, 2000, 24 (01) :57-60

[64] ALL-TRANS-RETINOIC ACID FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA [J].

KANAMARU, A ;

TAKEMOTO, Y ;

TANIMOTO, M ;

MURAKAMI, H ;

ASOU, N ;

KOBAYASHI, T ;

KURIYAMA, K ;

OHMOTO, E ;

SAKAMAKI, H ;

TSUBAKI, K ;

HIRAOKA, A ;

YAMADA, O ;

OH, H ;

SAITO, K ;

MATSUDA, S ;

MINATO, K ;

UEDA, T ;

OHNO, R .

BLOOD, 1995, 85 (05) :1202-1206

[65] Neurotrophic 3,9-bis[(alkylthio)methyl]- and -bis(alkoxymethyl)-K-252a derivatives [J].

Kaneko, M ;

Saito, Y ;

Saito, H ;

Matsumoto, T ;

Matsuda, Y ;

Vaught, JL ;

Dionne, CA ;

Angeles, TS ;

Glicksman, MA ;

Neff, NT ;

Rotella, DP ;

Kauer, JC ;

Mallamo, JP ;

Hudkins, RL ;

Murakata, C .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) :1863-1869

[66] FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model [J].

Kelly, LM ;

Liu, Q ;

Kutok, JL ;

Williams, IR ;

Boulton, CL ;

Gilliland, DG .

BLOOD, 2002, 99 (01) :310-318

[67] PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model [J].

Kelly, LM ;

Kutok, JL ;

Williams, IR ;

Boulton, CL ;

Amaral, SM ;

Curley, DP ;

Ley, TJ ;

Gilliland, DG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (12) :8283-8288

[68] Genetic's of myeloid leukemias [J].

Kelly, LM ;

Gilliland, DG .

ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, 2002, 3 :179-198

[69] CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) [J].

Kelly, LM ;

Yu, JC ;

Boulton, CL ;

Apatira, M ;

Li, J ;

Sullivan, CM ;

Williams, I ;

Amaral, SM ;

Curley, DP ;

Duclos, N ;

Neuberg, D ;

Scarborough, RM ;

Pandey, A ;

Hollenbach, S ;

Abe, K ;

Lokker, NA ;

Gilliland, DG ;

Giese, NA .

CANCER CELL, 2002, 1 (05) :421-432

[70] Histone deacetylase inhibitors: from target to clinical trials [J].

Kelly, WK ;

O'Connor, OA ;

Marks, PA .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (12) :1695-1713

← 2 3 4 5 6 7 8 9 10 11 →